AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15592334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10812378 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified‐fat diet high in monounsaturated fat
Number of subjects: 28
Study 10812378 — intervention group
Group type: COMPARATOR
Intervention: Low‐fat/high‐carbohydrate diet
Number of subjects: 28
Study 8831412 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg pilsicainide
Number of subjects: 75
Study 8831412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 1395659 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0
Study 1395659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4006252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap 845 (D)
Number of subjects: 0
Study 4006252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentron (S)
Number of subjects: 0
Study 4006252 — intervention group
Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer (SMS)
Number of subjects: 0
Study 31002449 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry condition
Number of subjects: 120
Study 31002449 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy condition
Number of subjects: 120
Study 30194618 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion sonohysterography (SIS)
Number of subjects: 750
Study 30194618 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingogram (HSG)
Number of subjects: 750
Study 30194618 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingogram (HSG) vs Saline infusion sonohysterography (SIS)
Number of subjects: 750
Study 27907814 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 75mg BID
Number of subjects: 42
Study 27907814 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 160mg OD
Number of subjects: 42
Study 27907814 — intervention group
Group type: COMPARATOR
Intervention: ASA 75mg OD
Number of subjects: 42
Study 25701561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive five-drug cART regimen (raltegravir 400 mg and maraviroc 150 mg twice daily, plus tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, darunavir 800 mg, and ritonavir 100 mg once daily)
Number of subjects: 110
Study 25701561 — intervention group
Group type: COMPARATOR
Intervention: Standard triple-drug cART regimen (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, darunavir 800 mg, and ritonavir 100 mg once daily)
Number of subjects: 110
Study 25701561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive five-drug cART regimen
Number of subjects: 110
Study 25701561 — intervention group
Group type: COMPARATOR
Intervention: Standard triple-drug cART regimen
Number of subjects: 110
Study 24030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Full prescription coverage
Number of subjects: 1052
Study 24030410 — intervention group
Group type: COMPARATOR
Intervention: Usual formulary coverage
Number of subjects: 1052
Study 21398421 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine attack-related information
Number of subjects: 9427
Study 21398421 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed migraine-specific information
Number of subjects: 9427
Study 18182928 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem
Number of subjects: 40
Study 18182928 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40
Study 18182928 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 40
Study 16556417 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 group treated with BAL+MARS
Number of subjects: 120
Study 16556417 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 group treated with BAL+SPE+CHDF
Number of subjects: 120
Study 16556417 — intervention group
Group type: EXPERIMENTAL
Intervention: H3 group treated with BAL+SPE+HP
Number of subjects: 120
Study 16556417 — intervention group
Group type: COMPARATOR
Intervention: C1 group treated with MARS
Number of subjects: 120
Study 16556417 — intervention group
Group type: COMPARATOR
Intervention: C2 group treated with SPE+CHDF
Number of subjects: 120
Study 16556417 — intervention group
Group type: COMPARATOR
Intervention: C3 group treated with SPE+HP
Number of subjects: 120
Study 12597751 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare‐funded quality improvement project involving monitoring of patient outcomes, feedback of performance data, and education of clinicians at dialysis centers.
Number of subjects: 58700
Study 10677921 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of 350 mg Euphyllin Retard at 8:00 A.M.
Number of subjects: 9
Study 10677921 — intervention group
Group type: COMPARATOR
Intervention: Evening administration of 350 mg Euphyllin Retard at 8:00 P.M.
Number of subjects: 9
Study 8610865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 61
Study 8610865 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 61
Study 1421063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (5 mg/dose)
Number of subjects: 36
Study 1421063 — intervention group
Group type: COMPARATOR
Intervention: CaCl2 (200 mg/dose)
Number of subjects: 36
Study 1421063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3840245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 17
Study 3840245 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study 3840245 — intervention group
Group type: EXPERIMENTAL
Intervention: Encircling scleral buckling techniques
Number of subjects: 17
Study 31358441 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-applied eyelid massage (Eyepeace)
Number of subjects: 20
Study 31358441 — intervention group
Group type: COMPARATOR
Intervention: Manual eyelid massage
Number of subjects: 20
Study 29400652 — intervention group
Group type: EXPERIMENTAL
Intervention: BuMA sirolimus-eluting stent (SES)
Number of subjects: 2348
Study 29400652 — intervention group
Group type: COMPARATOR
Intervention: Excel sirolimus-eluting stent (SES)
Number of subjects: 2348
Study 27689688 — intervention group
Group type: EXPERIMENTAL
Intervention: Navy beans (NB) consumption (35 g/day)
Number of subjects: 29
Study 27689688 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran (RB) consumption (30 g/day)
Number of subjects: 29
Study 27689688 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional ingredient)
Number of subjects: 29
Study 24985882 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Rituximab (MR)
Number of subjects: 201
Study 24985882 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 201
Study 21926583 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 465
Study 21926583 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-gluconate-impregnated sponge
Number of subjects: 465
Study 21926583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligon catheter
Number of subjects: 465
Study 21926583 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular catheter insertion
Number of subjects: 465
Study 21926583 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral catheter insertion
Number of subjects: 465
Study 20931804 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 30
Study 20931804 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus metformin
Number of subjects: 30
Study 19006900 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 received the lesson and watched a locally developed SBS video.
Number of subjects: 46
Study 19006900 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 received the lesson and watched a true dramatization of SBS created by a national organization.
Number of subjects: 46
Study 19006900 — intervention group
Group type: COMPARATOR
Intervention: Group 1 received a short lesson about SBS.
Number of subjects: 46
Study 16115394 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - fluticasone propionate (FP) 250 microg bid for moderate asthma and 375 microg bid for severe asthma (Group G)
Number of subjects: 86
Study 16115394 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS) - half doses of fluticasone propionate (FP) 125 microg bid for moderate asthma and 125 microg in the morning, 250 microg in the evening for severe asthma (Group H)
Number of subjects: 86
Study 16115394 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - fluticasone propionate (FP) (Group G)
Number of subjects: 86
Study 16115394 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS) - half doses of fluticasone propionate (FP) (Group H)
Number of subjects: 86
Study 12796125 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Cp-HSP60 seropositivity
Number of subjects: 339
Study 12796125 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Cp seropositivity
Number of subjects: 339
Study 12796125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cp-HSP60 IgG levels at follow-up
Number of subjects: 339
Study 12796125 — intervention group
Group type: COMPARATOR
Intervention: Correlation of Cp-HSP60 IgG with TnT and hs-CRP
Number of subjects: 339
Study 10802126 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg bid)
Number of subjects: 500
Study 10802126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 7969211 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/day)
Number of subjects: 18
Study 7969211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3659581 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol
Number of subjects: 8
Study 3659581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31544735 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Package community development activities
Number of subjects: 1333
Study 31544735 — intervention group
Group type: COMPARATOR
Intervention: Partial Package (livestock training and nutrition education)
Number of subjects: 1333
Study 31544735 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1333
Study 29561511 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual treatment of children under 12 with azithromycin (20 mg/kg up to 1 g in adults)
Number of subjects: 404
Study 29561511 — intervention group
Group type: COMPARATOR
Intervention: Annual treatment of everyone with azithromycin (20 mg/kg up to 1 g in adults)
Number of subjects: 404
Study 29561511 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual treatment of children under 12 with azithromycin
Number of subjects: 404
Study 25563238 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive anaesthesia
Number of subjects: 41
Study 25563238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypotensive anaesthesia)
Number of subjects: 41
Study 23579521 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness gastroplication (Plicator group)
Number of subjects: 70
Study 23579521 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic antireflux surgery (LARS group)
Number of subjects: 70
Study 21753160 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily prednisone (0.75 mg/kg/day)
Number of subjects: 64
Study 21753160 — intervention group
Group type: COMPARATOR
Intervention: Weekend prednisone (10 mg/kg/wk)
Number of subjects: 64
Study 19210142 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 194
Study 19210142 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 194
Study 19210142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 16714386 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin (r-metHuLeptin) administered during fasting
Number of subjects: 7
Study 16714386 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered during fasting
Number of subjects: 7
Study 15197803 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa, busulfan, and cyclophosphamide (TBC)
Number of subjects: 186
Study 15197803 — intervention group
Group type: COMPARATOR
Intervention: High-dose melphalan (HDM)
Number of subjects: 186
Study 11706112 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 782
Study 11706112 — intervention group
Group type: COMPARATOR
Intervention: Levodopa plus dopa decarboxylase inhibitor
Number of subjects: 782
Study 10567624 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ozone (200 ppb)
Number of subjects: 20
Study 8704426 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhuchun Pill (ZCP)
Number of subjects: 45
Study 8704426 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch capsule)
Number of subjects: 45
Study 2490739 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation the afternoon before surgery
Number of subjects: 23
Study 2490739 — intervention group
Group type: COMPARATOR
Intervention: Preparation the morning of surgery
Number of subjects: 23
Study 778433 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q7 intravenous injection (50 to 100 mg daily for 3 to 35 days)
Number of subjects: 55
Study 778433 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q7 oral administration (60 mg daily for 14 to 196 days)
Number of subjects: 55
Study 778433 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 oral administration (30 mg daily for 7 to 182 days)
Number of subjects: 55
Study 31820559 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study 31331568 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond sachet (40 g/day for 20 days)
Number of subjects: 50
Study 31331568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (wheat flour sachet)
Number of subjects: 50
Study 29173737 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Family Interaction Therapy (PFIT)
Number of subjects: 62
Study 29173737 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 62
Study 26156274 — intervention group
Group type: COMPARATOR
Intervention: WL radiograph
Number of subjects: 153
Study 26156274 — intervention group
Group type: EXPERIMENTAL
Intervention: Raypex5 EAL
Number of subjects: 153
Study 22517646 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (IP)
Number of subjects: 95
Study 22517646 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 95
Study 21258153 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3480 5 mg
Number of subjects: 567
Study 21258153 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3480 20 mg
Number of subjects: 567
Study 21258153 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3480 35/100 mg
Number of subjects: 567
Study 21258153 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg (active comparator)
Number of subjects: 567
Study 21258153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study 19769666 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 1%
Number of subjects: 50
Study 19769666 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 2%
Number of subjects: 50
Study 19769666 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 3%
Number of subjects: 50
Study 19769666 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 4%
Number of subjects: 50
Study 19769666 — intervention group
Group type: COMPARATOR
Intervention: Control (tap water)
Number of subjects: 50
Study 16391376 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (180 micro/kg bolus x 2, 10 minutes apart, then 2 micro/kg/min infusion over 18 hours)
Number of subjects: 42
Study 16391376 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin (60 Units per kg, target ACT 200-250 sec)
Number of subjects: 42
Study 16391376 — intervention group
Group type: COMPARATOR
Intervention: High-dose unfractionated heparin (100 Units per kg, target ACT 300-400 sec)
Number of subjects: 42
Study 16391376 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (LDH+I group)
Number of subjects: 42
Study 12781889 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the great auricular nerve (GAN) during parotidectomy
Number of subjects: 81
Study 12781889 — intervention group
Group type: COMPARATOR
Intervention: Division of the great auricular nerve (GAN) during parotidectomy
Number of subjects: 81
Study 10920165 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoallergenic infant formulas
Number of subjects: 0
Study 10920165 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formulas
Number of subjects: 0
Study 9057565 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic isoxazolyl penicillins (n=17)
Number of subjects: 59
Study 9057565 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic isoxazolyl penicillins (n=21)
Number of subjects: 59
Study 9057565 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement (TKR) patients (n=21)
Number of subjects: 59
Study 9057565 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement (THR) patients (n=38)
Number of subjects: 59
Study 8501499 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (2.5 mg, 5.0 mg, and 10.0 mg tablets over 12 weeks)
Number of subjects: 162
Study 8501499 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 162
Study 8501499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 3567973 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine (ara-C) 3 g/m2 infused over 2 hours
Number of subjects: 11
Study 3567973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (ara-C) 3 g/m2 infused over 2 hours with amsacrine (m-AMSA) 30 mg/m2 infused over 1 hour
Number of subjects: 11
Study 30003598 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 × 6 mm implants (test group; N = 108)
Number of subjects: 95
Study 30003598 — intervention group
Group type: COMPARATOR
Intervention: 4.0 × 11 mm implants (control group; N = 101)
Number of subjects: 95
Study 30003598 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 × 6 mm implants (test group)
Number of subjects: 95
Study 30003598 — intervention group
Group type: COMPARATOR
Intervention: 4.0 × 11 mm implants (control group)
Number of subjects: 95
Study 27601503 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Ankle Replacement (TAR)
Number of subjects: 328
Study 27601503 — intervention group
Group type: COMPARATOR
Intervention: Ankle Arthrodesis (fusion)
Number of subjects: 328
Study 27601503 — intervention group
Group type: EXPERIMENTAL
Intervention: TAR and Ankle Arthrodesis
Number of subjects: 328
Study 23896590 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic documentation system
Number of subjects: 16
Study 22851064 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine dye
Number of subjects: 699
Study 22851064 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigo carmine dye
Number of subjects: 699
Study 22851064 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid‐indigo carmine mixture dye
Number of subjects: 699
Study 22851064 — intervention group
Group type: COMPARATOR
Intervention: Conventional gastroscopic observation with white light
Number of subjects: 699
Study 22851064 — intervention group
Group type: COMPARATOR
Intervention: Magnification alone
Number of subjects: 699
Study 22851064 — intervention group
Group type: COMPARATOR
Intervention: Magnifying NBI observation
Number of subjects: 699
Study 20204966 — intervention group
Group type: EXPERIMENTAL
Intervention: Single implementation intention
Number of subjects: 650
Study 20204966 — intervention group
Group type: EXPERIMENTAL
Intervention: Second implementation intention at 3 months
Number of subjects: 650
Study 20204966 — intervention group
Group type: COMPARATOR
Intervention: Passive control condition
Number of subjects: 650
Study 20204966 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 650
Study 20204966 — intervention group
Group type: EXPERIMENTAL
Intervention: FFQ measure
Number of subjects: 650
Study 18396390 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquisolid tablet formulation of famotidine
Number of subjects: 0
Study 18396390 — intervention group
Group type: COMPARATOR
Intervention: Marketed famotidine tablets
Number of subjects: 0
Study 15988707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (20%) with heparin sodium
Number of subjects: 7
Study 15988707 — intervention group
Group type: COMPARATOR
Intervention: Saline and heparin sodium
Number of subjects: 7
Study 15988707 — intervention group
Group type: COMPARATOR
Intervention: Saline only
Number of subjects: 7
Study 12883930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, individualised outpatient rehabilitation program for 6 weeks
Number of subjects: 111
Study 12883930 — intervention group
Group type: COMPARATOR
Intervention: Control group (previously trained in a home exercise program)
Number of subjects: 111
Study 10232714 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg x kg(‐1) i.v. (Group P)
Number of subjects: 88
Study 10232714 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 8% in nitrous oxide 50% and oxygen (Group S)
Number of subjects: 88
Study 10232714 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 88
Study 10232714 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (Group S)
Number of subjects: 88
Study 10232714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 8780325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 8780325 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 8780325 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol
Number of subjects: 0
Study 8780325 — intervention group
Group type: COMPARATOR
Intervention: Beta blockers
Number of subjects: 0
Study 1856488 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cell combined with cholera B subunit vaccine (WC/BS)
Number of subjects: 0
Study 1856488 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cell only vaccine (WC)
Number of subjects: 0
Study 1856488 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0